Funder: Alnylam Pharmaceuticals
Due Dates: Rolling (apply at least 45 days before activity start date)
Funding Amounts: No fixed maximum; awards may be partial and vary by proposal; funding is determined case-by-case.
Summary: Supports independent, evidence-based educational activities for healthcare professionals in ATTR amyloidosis, AHP, and PH1 to improve patient care.
Key Information: Applications are for organizations only (not individuals); must align with Alnylam’s therapeutic areas of interest.